Table 5.

Effects of intervention on prevention of cross allergy

Indices	Descriptions of outcomes
Number of drug counseling sessions about cross allergy from doctors and nurses	Decreased by 67% (an average of 60 cases monthly before August 2008 versus an average of 20 cases monthly since August 2009).
Awareness rate of special cases of cross allergy	If doctors, pharmacists, and nurses did not read the prescribing information, almost no one knew of any contraindications for use of vancomycin in patients who are allergic to aminoglycosides, use of metoclopramide in patients who are allergic to procaine, and use of piperacillin/tazobactam in patients with an allergy to cephalosporins before August 2008. Awareness of such types of cross allergy increased to 100% in August 2009.
Percentage of questions on cross allergy correctly answered first time round by pharmacists	Increased by 30% (60% before August 2008 versus 90% in August 2009).
Number of medical errors related to cross allergy	Decreased by 97% (10 cases monthly before August 2008 versus three cases yearly in 2012).
Percentage of documentation on hypersensitivity in clinical notes	About 20% before August 2008 versus 100% after introduction of a formal history sheet in May 2012.
Risk rating	Decreased significantly [initial risk rating:25(high-risk) before August 2008 versus final risk rating:6 (medium-risk) in December 2012].